Skip to content
Menu

Alto Neuroscience, Inc. ANRO

Full chart Compare
Set alert

Price alert · ANRO

All alert types
25.39 USD -1.12 (-4.22%)

As ofNov 20, 2026, 11:33 AM EST

25.30 Day range 25.30
12.51 52-week range 37.48
YTD
+42.64%
1 year
+79.43%

 

No chart data for this range yet.
Market cap
1.01B
EPS (ttm)
-2.32
Shares out
40.11M
Forward P/E
-8.95
YTD return
+42.64%
1-year return
+79.43%
50-day average
25.82
200-day average
24.89
Enterprise value
737.94M
Price / book
3.57
Volume
68.24K
Avg volume
611.30K
Open
25.30
Previous close
26.51
Day's range
25.30 – 25.30
52-week range
12.51 – 37.48
Beta
1.45
Analysts
Strong Buy
Price target
38.67 (+52.3%)
Earnings date
Mar 15, 2027

Key statistics

Free cash flow
-50.34M
Total cash
319.34M
Total debt
18.02M
Return on equity
-46.65%
Short % of float
16.60%

Fundamental scorecard

3 of 25 checks passed on ANRO’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ANRO Revenue — quarterly 0
ANRO Net income — quarterly -25.12M
ANRO EPS — quarterly -0.54

Earnings

ANRO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 15, 2027Dec 30, 2026-0.54———
Nov 10, 2026Sep 30, 2026-0.67354-0.54+0.13+19.83%
Aug 12, 2026Jun 30, 2026-0.73454-0.65+0.08+11.51%
May 13, 2026Mar 31, 2026-0.56-0.80-0.24-42.86%
Mar 16, 2026Dec 31, 2025-0.56-0.45+0.11+19.64%
Nov 12, 2025Sep 30, 2025-0.66-0.52+0.14+21.21%

Upgrades / downgrades

ANRO analyst upgrades and downgrades
DateFirmActionFromTo
Nov 11, 2026BTIGreitBuyBuy
Oct 19, 2026HC Wainwright & Co.mainBuyBuy
Aug 17, 2026HC Wainwright & Co.mainBuyBuy
Aug 13, 2026WedbushmainNeutralNeutral
Aug 13, 2026BTIGmainBuyBuy
May 18, 2026BairdmainOutperformOutperform

About Alto Neuroscience, Inc.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on ANRO — it syncs with the Stock Master app.

Insider holders

ANRO insider holders
InsiderRelationLatest transactionDateShares held
ETKIN AMITChief Executive OfficerStock GiftMay 13, 2026833,949
HANLEY MICHAEL CONICK JR.Chief Operating OfficerSaleNov 17, 20260
SMITH NICHOLAS CONRADPresidentConversion of Exercise of derivative securityOct 1, 202679,060

Institution ownership

ANRO institution ownership
Holder% heldSharesValueReported
Alpha Wave Global, LP9.24%3,707,75798.11MSep 29, 2026
Blackrock Inc.6.80%2,726,10672.13MSep 29, 2026
Commodore Capital Lp6.79%2,723,19672.06MSep 29, 2026
EcoR1 Capital, LLC5.56%2,232,00059.06MSep 29, 2026
Perceptive Advisors Llc4.39%1,760,95046.59MSep 29, 2026
Adage Capital Partners GP L.L.C.4.24%1,701,91345.03MSep 29, 2026

Fund ownership

ANRO fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.52%1,011,88126.77MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.09%836,52222.13MSep 29, 2026
Franklin Strategic Series-Franklin Biotechnology Discovery Fund0.87%347,9049.21MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund0.86%346,6189.17MJun 29, 2026
iShares Trust-iShares Russell 2000 Growth ETF0.74%298,2737.89MSep 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.72%287,0337.59MAug 30, 2026